A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)-Reference-Cited by-同舟云学术

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)

Published:2020-12 Issue: Volume:54 Page:121-126
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Park Min Ho^ORCID,Lee Soo Jung,Noh Woo Chul,Jeon Chang Wan,Lee Seok Won,Son Gil Soo,Moon Byung-In,Lee Jin Sun,Kang Sung Soo,Suh Young Jin,Gwak Geumhee,Kim Tae Hyun,Yoo Young Bum,Kim Hyun-Ah^ORCID,Kim Min Young^ORCID,Kim Ju Yeon,Jeong Joon^ORCID

Funder

Eisai Korea Inc

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference27 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Updates on cancer epidemiology in Korea;Kweon;Chonnam Med J,2018

3. The changing global patterns of female breast cancer incidence and mortality;Bray;Breast Cancer Res,2004

4. Metastatic breast cancer;Peart;Radiol Technol,2017

5. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth;Jordan;Mol Canc Therapeut,2005

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer;Breast Cancer Research and Treatment;2021-11-29

2. Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study;Therapeutic Advances in Medical Oncology;2021-01